GlaxoSmithKline submits revised disclosure

22 Mar 2017 Evaluate

The Exchange has now received the revised disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1) (a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for GlaxoSmithKline.

The above information is a part of company’s filings submitted to BSE.

Glaxosmithkline Phar Share Price

2624.40 -26.45 (-1.00%)
26-Feb-2026 14:22 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1779.90
Dr. Reddys Lab 1317.65
Cipla 1351.55
Zydus Lifesciences 935.25
Lupin 2315.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×